TNGX vs. AMRX, XENE, ARWR, VKTX, CRNX, RARE, MOR, NAMS, HCM, and BHC
Should you be buying Tango Therapeutics stock or one of its competitors? The main competitors of Tango Therapeutics include AMNEAL PHARMACEUTICALS (AMRX), Xenon Pharmaceuticals (XENE), Arrowhead Pharmaceuticals (ARWR), Viking Therapeutics (VKTX), Crinetics Pharmaceuticals (CRNX), Ultragenyx Pharmaceutical (RARE), MorphoSys (MOR), NewAmsterdam Pharma (NAMS), HUTCHMED (HCM), and Bausch Health Cos (BHC). These companies are all part of the "pharmaceutical products" industry.
Tango Therapeutics vs. Its Competitors
AMNEAL PHARMACEUTICALS (NASDAQ:AMRX) and Tango Therapeutics (NASDAQ:TNGX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.
AMNEAL PHARMACEUTICALS has a net margin of 0.12% compared to Tango Therapeutics' net margin of -599.11%. Tango Therapeutics' return on equity of -79.72% beat AMNEAL PHARMACEUTICALS's return on equity.
AMNEAL PHARMACEUTICALS has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Tango Therapeutics has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500.
31.8% of AMNEAL PHARMACEUTICALS shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 26.6% of AMNEAL PHARMACEUTICALS shares are owned by insiders. Comparatively, 7.5% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
AMNEAL PHARMACEUTICALS has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than AMNEAL PHARMACEUTICALS, indicating that it is currently the more affordable of the two stocks.
In the previous week, AMNEAL PHARMACEUTICALS had 12 more articles in the media than Tango Therapeutics. MarketBeat recorded 19 mentions for AMNEAL PHARMACEUTICALS and 7 mentions for Tango Therapeutics. AMNEAL PHARMACEUTICALS's average media sentiment score of 1.06 beat Tango Therapeutics' score of 0.35 indicating that AMNEAL PHARMACEUTICALS is being referred to more favorably in the media.
AMNEAL PHARMACEUTICALS presently has a consensus target price of $11.60, suggesting a potential upside of 21.47%. Tango Therapeutics has a consensus target price of $10.50, suggesting a potential upside of 53.96%. Given Tango Therapeutics' higher possible upside, analysts plainly believe Tango Therapeutics is more favorable than AMNEAL PHARMACEUTICALS.
Summary
AMNEAL PHARMACEUTICALS beats Tango Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Tango Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tango Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TNGX) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access